Superworth

CorMedix price to book ratio CRMD

Market value divided by the book value of the company's net assets, since 2011.

Today, Oct 23, 2026
1.3×
10-year median
3.5×
Against its 10-year history
2nd
percentile: 0 is its lowest day, 100 its highest
10-year range
1.2× to 61.4×
Peer median
2.5×

CorMedix's price to book ratio is 1.3× as of Oct 23, 2026.

That is below its ten-year median of 3.5×, lower than on 98% of days in the last ten years.

Over that time it ranged from 1.2× in May 2017 to 61.4× in Aug 2018.

The median for 10 large drugmakers of a similar size is 2.5×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far1.3×1.2×2.6×
20252.6×2.0×12.8×
20248.5×2.0×15.8×
20232.5×2.2×4.9×
20223.1×1.8×4.7×
20212.5×2.3×16.4×
20206.9×3.0×10.2×
20196.4×5.0×13.3×
201857.5×2.0×61.4×
20173.5×1.2×4.1×
20162.6×1.2×4.4×
20152.0×1.8×60.3×
20146.7×5.5×6.7×
2013n/m a value too high to mean anything
20124.9×2.7×8.5×
20114.3×1.1×5.6×

Against its peers

Companies in Drug Manufacturers - General nearest CorMedix's size, closest first, today.

CompanyPrice to book ratio
CRMDCorMedix1.3×
ZVRAZevra Therapeutics2.7×
IRWDIronwood Pharmaceuticalsn/m
PBYIPuma Biotechnology4.1×
COLLCollegium Pharmaceutical2.4×
ARVNArvinas0.8×
ABUSArbutus Biopharma3.2×
AMPHAmphastar Pharmaceuticals1.4×
OMEROmerosn/m
PCRXPacira BioSciences2.2×
ANABAnaptysbio138×
Peer median2.5×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on CorMedix

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.